Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma 

Jérôme Fayette,1 Yann Molin,1 Emilie Lavergne,2 Xavier Montbarbon,3 Séverine Racadot,3 Marc Poupart,4 Antoine Ramade,5 Philippe Zrounba,6 Philippe Ceruse,7 Pascal Pommier31Department of Medicine, 2Biostatistics Unit, 3Department of Radiotherapy, Centre Léon...

Full description

Bibliographic Details
Main Authors:	Fayette J, Molin Y, Lavergne E, Montbarbon X, Racadot S, Poupart M, Ramade A, Zrounba P, Ceruse P, Pommier P
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-11-01
Series:	Drug Design, Development and Therapy
Online Access:	https://www.dovepress.com/radiotherapy-potentiation-with-weekly-cisplatin-compared-to-standard-e-peer-reviewed-article-DDDT

Similar Items

Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma.
by: Chang-Juan Tao, et al.
Published: (2014-01-01)

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis
by: Seth Helfenstein, et al.
Published: (2019-02-01)

Concurrent Weekly versus Three Weekly Cisplatin with Radiotherapy in Locally Advanced Uterine Cervical Carcinoma.
by: Md. Rakibul Hasan, et al.
Published: (2018-10-01)

The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity
by: Tsan Din-Li, et al.
Published: (2012-12-01)

Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma
by: Adity Chakraborty, et al.
Published: (2021-07-01)

Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine
by: Chen Y, et al.
Published: (2020-12-01)

A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence
by: Qi Liu, et al.
Published: (2020-04-01)

Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis
by: Jun-Fang Liao, et al.
Published: (2019-06-01)

Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer
by: Pramod Kumar Gupta, et al.
Published: (2016-01-01)

Concurrent weekly single cisplatin vs triweekly cisplatin alone with radiotherapy for treatment of locally advanced cervical cancer: a meta-analysis
by: Zhu J, et al.
Published: (2018-07-01)

A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer
by: Charafeddine Maya, et al.
Published: (2010-09-01)

Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
by: Jun-Fang Liao, et al.
Published: (2019-09-01)

Weekly nanoparticle albumin bound-paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
by: Wang HY, et al.
Published: (2016-09-01)

Introspection to abandon the 'Comfort Zone': Weekly cisplatin no more
by: Avinash Pandey, et al.
Published: (2018-01-01)

Once-a-week versus once-every-3-weeks cisplatin in patients receiving chemoradiation for locally advanced head-and-neck cancer: A survey of practice in India
by: Gautam Goyal, et al.
Published: (2018-01-01)

Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
by: Yuan Zhang, et al.
Published: (2019-06-01)

Laser Profilometry Aiding Smart Vehicle Control
by: Cosimo Patruno, et al.
Published: (2014-12-01)

Daily Cisplatin and Weekly Docetaxel versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial
by: Yuichiro Hayashi, et al.
Published: (2018-07-01)

The Influence of Cisplatin Dose upon Survival in Concurrent Chemoradiotherapy of Locally Advanced Cervical Carcinoma with Weekly Cisplatin
by: Igor Sirák, et al.
Published: (2008-01-01)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
by: Moon Jin Kim, et al.
Published: (2019-09-01)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
by: Shogo Shinohara, et al.
Published: (2021-10-01)

Medical cannabis ‒ the Canadian perspective 
by: Ko GD, et al.
Published: (2016-09-01)

A prospective randomized study comparing concurrent chemoradiation with weekly and 3 weekly cisplatin in locally advanced oropharyngeal carcinoma
by: R Nanda, et al.
Published: (2019-01-01)

Concurrent Chemoradiation With Weekly Gemcitabine and Cisplatin in Locally Advanced Cervical Cancer
by: Esmati E, et al.
Published: (2011-12-01)

Long Non-Coding RNA NNT-AS1 Contributes to Cisplatin Resistance via miR-1236-3p/ATG7 Axis in Lung Cancer Cells
by: Wang H, et al.
Published: (2020-04-01)

Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
by: Kireeva G, et al.
Published: (2021-05-01)

Hyperfractionated Radiotherapy with Concurrent Cisplatin/5-Fluorouracil for Locoregional Advanced Head and Neck Cancer: Analysis of 105 Consecutive Patients
by: David Zaboli, et al.
Published: (2012-01-01)

Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis
by: Zhang M, et al.
Published: (2015-06-01)

PLGA-encapsulated tea polyphenols enhance the chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing Ehrlich ascites carcinoma
by: Singh M, et al.
Published: (2015-10-01)

Telomere length in blood cells is related to the chronicity, severity, and recurrence rate of schizophrenia
by: Pawelczyk T, et al.
Published: (2015-06-01)

Association analysis of polymorphisms in STARD6 and near ECHDC3 in Alzheimer’s disease patients carrying the APOE ε4 Allele
by: Yin J, et al.
Published: (2019-01-01)

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma
by: Kailin Wang, et al.
Published: (2019-05-01)

Weekly chemotherapy with cisplatin and paclitaxel in advanced NSCLC: a phase II study
by: G. Buccheri, et al.
Published: (2016-02-01)

Progressive retinal detachment secondary to juxtapapillary microholes in association with type 3 posterior staphylomas
by: Dinah CB, et al.
Published: (2014-06-01)

Genetic polymorphisms of PAI-1 and PAR-1 are associated with acute normal tissue toxicity in Chinese rectal cancer patients treated with pelvic radiotherapy
by: Zhang H, et al.
Published: (2015-08-01)

Zonisamide in the management of epilepsy in the elderly
by: Romigi A, et al.
Published: (2015-06-01)

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma
by: Ting Jin, et al.
Published: (2019-04-01)

Cervical Ossification of Ligamentum Flavum: Elaborating an Underappreciated but Occasional Contributor to Myeloradiculopathy in Aging Population Based on Synthesis of Individual Participant Data
by: Zhang B, et al.
Published: (2021-05-01)

Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
by: Himani Aggarwal, et al.
Published: (2020-06-01)

Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats
by: Lozano-Pérez AA, et al.
Published: (2014-09-01)